Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

ClinicalTrials.gov ID: NCT00314132

Public ClinicalTrials.gov record NCT00314132. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomised, Double Blind, Multicentre, Placebo Controlled Phase III Study of the Safety and Tolerability Following Administration of Live Attenuated JE Vaccine (ChimeriVax™-JE)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess whether ChimeriVax™ JE vaccine (a new vaccine to be used for vaccination against Japanese encephalitis) is safe and well tolerated when compared to placebo (dummy) vaccination.

Study identification

NCT ID: NCT00314132
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Sanofi; Industry
Enrollment: 2,004 participants

Conditions and interventions

Conditions

Interventions

ChimeriVax-JE, Japanese Encephalitis vaccine Biological
0.9% Saline Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2005 (Type not available)
Primary completion: Nov 2006 (Actual)
Completion: Nov 2006 (Actual)
Last update posted: Dec 6, 2012

2005 – 2006

United States locations

U.S. sites: 16
U.S. states: 10
U.S. cities: 16

Facility	City	State	ZIP	Site status
Not listed	Burbank	California	92505	—
Not listed	Costa Mesa	California	92708	—
Not listed	Davis	California	95616	—
Not listed	San Francisco	California	94102	—
Not listed	Vallejo	California	94589	—
Not listed	Miami	Florida	33173	—
Not listed	Orlando	Florida	32809	—
Not listed	Pembroke Pines	Florida	33024	—
Not listed	Iowa City	Iowa	52242	—
Not listed	Overland Park	Kansas	66212	—
Not listed	Bardstown	Kentucky	40004	—
Not listed	Livonia	Michigan	48152	—
Not listed	Sprnigfield	Missouri	65802	—
Not listed	Omaha	Nebraska	68134	—
Not listed	Winston-Salem	North Carolina	27109	—
Not listed	Fort Worth	Texas	76135	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00314132, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 6, 2012 · Synced Oct 25, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00314132 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →